Cytokinetics (CYTK) Depreciation & Amortization (CF) (2010 - 2026)

Cytokinetics (CYTK) has reported Depreciation & Amortization (CF) for 17 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) rose 46.87% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $11.2 million (up 17.93% YoY), while the FY2025 annual figure was $10.1 million, up 6.23% from the prior year.
• Depreciation & Amortization (CF) climbed to $3.4 million in Q1 2026 per CYTK's latest filing, from $2.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $6.3 million in Q4 2023 and bottomed at $1.3 million in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $2.4 million across 5 years, with a median of $2.3 million in 2025.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 282.09% — and 2024, when it slumped 62.38%.
• Cytokinetics' Depreciation & Amortization (CF) stood at $1.7 million in 2022, then soared by 282.09% to $6.3 million in 2023, then plunged by 62.38% to $2.4 million in 2024, then gained by 20.06% to $2.9 million in 2025, then rose by 18.07% to $3.4 million in 2026.
• Business Quant data shows CYTK's Depreciation & Amortization (CF) at $3.4 million in Q1 2026, $2.9 million in Q4 2025, and $2.7 million in Q3 2025.